Extracorporeal photopheresis for pembrolizumab-induced dermatitis: a case report

URN to cite this document:: urn:nbn:de:bvb:355-epub-770250
DOI to cite this document:: 10.5283/epub.77025

Zenderowski, Veronika ; Hutchinson, James A.

; Brosig, Andreas

; Haferkamp, Sebastian

; Kronenberg, Katharina

License: Creative Commons Attribution 4.0
PDF - Published Version
(974kB)

Date of publication of this fulltext: 02 Jul 2025 10:32

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

Immune-related adverse events (irAE) are common in checkpoint blockade–treated patients and limit its clinical application. Corticosteroids are the first-line therapy for treatment of irAE, but animal models clearly demonstrate that steroids diminish anti-programmed cell death protein 1 (PD-1)-induced tumour immunity. Better strategies to manage irAE while preserving anti-tumour immunity are ...